News | Stents Bioresorbable | March 11, 2016

Magnesium Elektron, Biotronik Partner to Develop Bioresorbable Alloy System

Ten-year research program led to development of SynerMag bioresorbable magnesium coronary scaffold

Biotronik, Magnesium Elektron, bioresorbable magnesium coronary scaffold, partner

Specially designed extrusion equipment at Magnesium Elektron’s purpose-built facility in England produces wire made from SynerMag bioresorbable magnesium alloy. Photo courtesy of Business Wire.

March 11, 2016 — Magnesium Elektron, developer, manufacturer and supplier of high-performance magnesium alloys, announced that Biotronik has been its partner in the development of its SynerMag bioresorbable magnesium alloys for cardiovascular application.

The two companies entered into a joint research and development program in 2006 aimed at developing a bioresorbable magnesium coronary scaffold. The ten-year research program has resulted in Elektron’s SynerMag 410 alloy system being used as the platform material in the Biotronik Magnesium Scaffold, what the company calls the world’s first clinically proven magnesium-based bioresorbable scaffold.

The latest generation Biotronik Magnesium Scaffold was clinically evaluated in the recent BIOSOLVE II study. The clinical data from BIOSOLVE II will be used to obtain CE approval for the device, and the release of the data was accompanied by publication in The Lancet.

Production of Elektron’s SynerMag 410 alloy system takes place in a new purpose-built manufacturing and testing facility in Manchester, United Kingdom. The facility, which achieved ISO 13485 approval in 2014, ensures Biotronik has a facility in its supply chain that will directly support its own production activities for the Biotronik Magnesium Scaffold.

For more information: www.biotronik.com, www.magnesium-elektron.com

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init